FDA Leaders Consider Abandoning Outside Expert Reviews of Drug Applications
The FDA under President Donald Trump is contemplating a major shift in policy regarding the review of drug applications. The agency is considering moving away from assembling panels of outside experts to evaluate and vote on individual drugs, a move that has sparked criticism from those who believe it will hinder public scrutiny of the agency’s decisions.
George Tidmarsh, head of the FDA’s Center for Drug Evaluation and Research, recently stated that he believes these advisory meetings on specific drugs are redundant and a significant amount of work for both the company and the FDA. Instead, he believes that time and resources should be focused on addressing broader questions within the industry.
The FDA’s advisory committees were established in 1972 to provide expert advice on technical decisions related to drug approval. These committees play a crucial role in reviewing evidence and voting on whether the FDA should approve drugs, vaccines, and medical devices. However, recent decisions, such as the approval of the controversial Alzheimer’s drug Aduhelm against the recommendation of the advisory committee, have raised concerns about the transparency of the FDA’s decision-making process.
While Tidmarsh has indicated that the committees will still be consulted on general issues, critics argue that eliminating the meetings on specific drugs will limit the public’s understanding of the FDA’s regulatory process. Former FDA officials and academics believe that these meetings are essential for FDA scientists to make informed decisions and provide an opportunity for public input on important regulatory matters.
The FDA’s decision to publish “complete response letters,” which detail the reasons for rejecting a drug application, is seen as a step towards transparency. However, many experts believe that these letters do not replace the need for advisory committee meetings, which provide a platform for in-depth discussion and debate on drug approvals.
Critics of the proposed changes fear that the FDA is moving towards consolidating power within the agency and reducing accountability to external experts and the public. The decrease in advisory committee meetings under the Trump administration has raised concerns about the agency’s commitment to transparency and public engagement in the drug approval process.
As the FDA continues to navigate these changes, it is essential for the agency to prioritize transparency, public engagement, and expert input in its decision-making process. The role of advisory committees in evaluating drug applications and ensuring the safety and efficacy of medications cannot be understated, and any changes to this process must be carefully considered to maintain the public’s trust in the FDA’s regulatory oversight.
